Drugs in Dev.
Dental and Oral Health
Phase I/ Phase II

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CS-002
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Complex Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)
Details : CS-002 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Canities.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2025
Lead Product(s) : CS-002
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Complex Science
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RiboX Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001
Details : RXRG001 is an AQP1 modulator, circular RNA, which is currently being evaluated for the treatment of patients with radiation-induced-xerostomia (RIX) and hyposalivation.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 09, 2025
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
Details : RXRG001 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AAV-AQP1
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : $30.0 million
Deal Type : Financing
Details : Sanofi will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, including AAV-AQP1, a gene therapy for xerostomia caused by Sjogren's syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : AAV-AQP1
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : $30.0 million
Deal Type : Financing

Lead Product(s) : Cannabidiol
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : CB21 Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
CBD Effects on Periodontal Health of Patients With Chronic Periodontitis
Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Chronic Periodontitis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 11, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : CB21 Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : KH001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients
Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dentin Sensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : KH001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AMY-101
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis
Details : AMY-101 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gingivitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 03, 2018
Lead Product(s) : AMY-101
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PerioSept (Taurolidine) is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Periodontitis.
Product Name : PerioSept
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 10, 2014
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Mighteaflow
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Green Tea Lozenges for the Management of Dry Mouth
Details : Mighteaflow is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 24, 2012
Lead Product(s) : Mighteaflow
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Autologous Bone Mesenchymal Stem Cell
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Sanidad de Castilla y León | University of Valladolid | CRMR Castilla y León | Citospin
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)
Details : Autologous Bone Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Maxillary Cyst.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 08, 2011
Lead Product(s) : Autologous Bone Mesenchymal Stem Cell
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Sanidad de Castilla y León | University of Valladolid | CRMR Castilla y León | Citospin
Deal Size : Inapplicable
Deal Type : Inapplicable
